



30-Day Countdown – Phase III, Lift 3: Retirement of the Transition Policy for Beneficiaries 22 Years of Age and Older

April 19, 2023

What Pharmacy Providers and Prescribers Need to Know


On May 19, 2023, Phase III, Lift 3 (P3/L3) will be implemented, lifting the Transition Policy for 22 Standard Therapeutic Classes (STCs). This is the third in a series of lifts to retire or phase out the grandfathering of historical prior authorizations (PAs) and claims by lifting the override of **NCPDP Reject Code 75 – Prior Authorization Required**.

The following 22 STCs will be impacted with implementation of P3/L3 on May 19, 2023:

Phase III, Lift 3 (P3/L3) Drug Classes *		
Anti-Ulcer Preps/ Gastrointestinal Preps (STC 01)	Other Antibiotics (STC 27)	Antiarthritics (STC 42)
Muscle Relaxants (STC 08)	Urinary Antibacterials (STC 28)	Fat Soluble Vitamins (STC 80)
Tetracyclines (STC 21)	Antiparasitics (STC 31)	Multivitamins (STC 82)
Penicillins (STC 22)	Antimalarials (STC 32)	Folic Acid Preparations (STC 83)
Streptomycins (STC 23)	Antivirals (STC 33)	Vitamin K (STC 85)

Phase III, Lift 3 (P3/L3) Drug Classes *		
Sulfonamides (STC 24)	TB Preparations (STC 34)	Antifungals (STC 94)
Erythromycins (STC 25)	General Antibacterials and Antiseptics (STC 38)	
Cephalosporins (STC 26)	Non-Opioid Analgesics (STC 41)	

* STC refers to the Standard Therapeutic Classification number.



- Beneficiaries 21 years of age and younger are exempt from Phase III: Retirement of the Transition Policy.
- Enteral nutrition products for beneficiaries of all ages are also exempt from Phase III: Retirement of the Transition Policy.

What Pharmacy Providers and Prescribers Need to Do

If a beneficiary is currently receiving a medication in the STCs identified for P3/L3 as listed in the table above, pharmacy providers and prescribers should prepare for the retirement of the Transition Policy in the following ways:

1. Consider covered therapies that may not require a PA, if clinically appropriate. Review the following:
 - [Medi-Cal Rx Contract Drugs Lists & Covered Products Lists](#)
 - [Medi-Cal Rx Approved NDC List](#)
 - Prescribers: Refer to your ePrescribing application.

2. If a change in therapy is not appropriate, submit a PA request via one of the approved Medi-Cal Rx Submission Methods:
 - [CoverMyMeds®](#)
 - [Medi-Cal Rx Secured Provider Portal](#)
 - NCPDP P4 Transaction
 - Fax
 - U.S. Mail

Resources

- For more information about Medi-Cal Rx Reinstatement, visit the [Medi-Cal Rx Education & Outreach](#) page on the [Medi-Cal Rx Web Portal](#) and select **Medi-Cal Rx Reinstatement**.
- Review the [Medi-Cal Rx Reinstatement of Prior Authorizations and Retirement of the Transition Policy: Phases II, III, and IV](#) slide deck.
- Review [Medi-Cal Rx Phased Reinstatement Frequently Asked Questions \(FAQs\)](#).
- Review the [Medi-Cal Rx Reinstatement Phases II–III](#) webinar recording.
- Review the [30-Day Countdown – Phase III, Lift 1: Retirement of the Transition Policy for Beneficiaries 22 Years of Age and Older](#) alert.
- Review the [30-Day Countdown – Phase III, Lift 2: Retirement of the Transition Policy for Beneficiaries 22 Years of Age and Older](#) alert.
- Refer to the [Medi-Cal Rx Bulletins & News](#) and [Medi-Cal Rx Forms & Information](#) pages of the [Medi-Cal Rx Web Portal](#) for guidance to successfully submit PAs.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@magellanhealth.com.